Intangible and Other Noncurrent Assets (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of Finite-Lived Intangible Assets And Other Noncurrent Assets

Intangible and other non-current assets consist of the following (in thousands):


	December 31, 2019						December 31, 2018
	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
PANCREAZE license (1)	$	141,895	$	(22,467)	$	119,428	$	141,895	$	(8,277)	$	133,618
Janssen patents (2)		3,050		(2,959)		91		3,050		(2,597)		453
Long-term receivables (3)		413		—		413		—		—		—
Other non-current assets (4)		208		—		208		208		—		208
Total	$	145,566	$	(25,426)	$	120,140	$	145,153	$	(10,874)	$	134,279

(1)

In June 2018, the Company acquired the rights to license PANCREAZE in the U.S. and Canada, as described further in Note 12. The rights are being amortized over their estimated useful life of 10 years using the straight-line method.

(2)

In September 2014, the Company acquired certain patents relating to Qsymia from Janssen Pharmaceuticals, approximately $3.1 million of which was recorded as an intangible asset. The patents are being amortized over their estimated useful life of 5.5 years using the straight-line method.

(3)

Long-term receivables consist of amounts not expected to be collected within a year of the balance sheet date.

(4)

Other non-current assets primarily consist of real estate deposits.

Future Expected Amortization Expenses For Intangible Assets

Future expected amortization expenses for intangible assets as of December 31, 2019 are as follows (in thousands):


2020	$	14,280
2021		14,190
2022		14,189
2023		14,190
2024		14,189
Thereafter		48,481
Total	$	119,519